<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peripheral blood stem cells (PBSC) were collected from 24 patients who were treated with high dose <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Studied patients included one with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 4 with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 1 with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 13 with <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 1 with malignant <z:mpath ids='MPATH_146,MPATH_652'>histiocytosis</z:mpath>, 2 with <z:mp ids='MP_0009440'>myeloma</z:mp>, and 4 with <z:e sem="disease" ids="C0039590" disease_type="Neoplastic Process" abbrv="">testicular tumor</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="4911">Etoposide</z:chebi> was infused at a dose of 500 mg/m2 for 4 days, followed by subcutaneous injection of recombinant human granulocyte-colony stimulating factor from the nadir of leukocyte </plain></SENT>
<SENT sid="3" pm="."><plain>PBSC were collected by processing 15-20 liters of blood apheresis in the recovery phase of chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, the number of CFU-GM collected per aphereresis ranged from 0.01 to 59.4 x 10(5)/kg, and more than 5 x 10(5)/kg CFU-GM were collected in 19 of the patients (73%) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients treated along with our protocols have remained in complete remission, but one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> relapsed within 1 month after the treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Ten <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients were assessable for antitumor effect, and complete response (CR) was observed in 2, partial response (PR) was 7, and no change (NC) in one patient </plain></SENT>
<SENT sid="7" pm="."><plain>Two patients with <z:mp ids='MP_0009440'>myeloma</z:mp> were classified to be NC </plain></SENT>
<SENT sid="8" pm="."><plain>Three of the 4 patients with <z:e sem="disease" ids="C0039590" disease_type="Neoplastic Process" abbrv="">testicular tumor</z:e> were PR, and the other one was NC </plain></SENT>
<SENT sid="9" pm="."><plain>Eleven patients subsequently underwent PBSCT </plain></SENT>
<SENT sid="10" pm="."><plain>The number of days required to achieve an absolute granulocyte count of 0.5 x 10(9)/l was 7 to 11 days, with a mean of 8.6 </plain></SENT>
</text></document>